Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Randomized Open Comparative Trial of Oral Sucrosomial Iron (SiderAl Forte®) and Oral Iron Sulphate (Duroferon®) to Blood Donors.

ID
Name
FOU2022-00167 980506
Description
2 different oral iron supplementations after blood donation are compared.
Trial arms
Trial start
2023-01-31
Estimated PCD
2025-01-01
Trial end
2026-01-01
Status
Active (not recruiting)
Treatment
Sucrosomial Iron
20 capsules of Sucrosomial Iron 30 mg is given after blood donation
Arms:
Oral sucrosomial Iron (SiderAl Forte®)
Other names:
SiderAl Forte®
Iron Sulfate
20 tablets of oral iron sulphate (Duroferon®) 100 mg is given after blood donation
Arms:
Oral iron sulphate (Duroferon®)
Other names:
Duroferon®
Size
120
Primary endpoint
Side effects
One year
Eligibility criteria
Inclusion Criteria: Blood donors at Uppsala University hospital wo have been donating blood regularly the last two years are eligible to participate in the study. Exclusion Criteria: Donors who cannot be accepted for blood donation anymore because they do not fulfill the Swedish criteria for blood donation.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Drugs:\n\nOral sucrosomial Iron (SiderAl Forte®) and oral iron sulphate (Duroferon®) to blood donors', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 120, 'type': 'ACTUAL'}}
Updated at
2024-05-08

1 organization

2 products

1 indication

Organization
Uppsala University Hospital
Product
Sucrosomial Iron
Indication
Blood Donation
Product
Iron Sulfate